Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: Retrospective analysis of 334 consecutive patients

European Journal of Haematology

Volumn 95, Issue 5, 2015, Pages 421-425

  Campregher, Paulo Vidal ^a   Hamerschlak, Nelson ^a   Colturato, Vergilio Antonio Renzi ^b   Mauad, Marcos Augusto ^b   de Souza, Mair Pedro ^c   da Silva Bouzas, Luis Fernando ^d   Tavares, Rita de Cássia B ^d   Barros, José Carlos ^e   Chiattone, Ricardo ^e   Paz, Alessandra ^f   Silla, Lucia ^f   Vigorito, Afonso Celso ^g   Miranda, Eliane ^g   Funke, Vaneuza Araújo Moreira ^h   Flowers, Mary Evelyn ⁱ  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b Fundação Dr Amaral Carvalho   (Brazil)

^c Hospital Amaral Carvalho   (Brazil)

^d Centro de Transplante de Medula Óssea CEMO   (Brazil)

^e FACULDADE DE CIÊNCIAS MÉDICAS DA SANTA CASA DE SÃO PAULO   (Brazil)

^f HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^g UNIVERSITY OF CAMPINAS   (Brazil)

^h FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

ⁱ USA   (United States)

Author keywords

Haematological neoplasms; Hematopoietic stem cell transplantation; Multicenter study; Peripheral blood stem cell transplantation

Indexed keywords

HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC GRAFT VERSUS HOST DISEASE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; LIVING DONOR; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ALLOGRAFT; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DONOR; FOLLOW UP; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; INFANT; MIDDLE AGED; MORTALITY; PRESCHOOL CHILD; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; ALLOGRAFTS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; INFANT; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DONORS;

EID: 84944513615     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12508     Document Type: Article

References (13)

1. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998;22:1145-51.
2. Schmitz N, Eapen M, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108:4288-90.
3. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000;355:1231-7.
4. Mielcarek M, Storer B, Martin PJ, et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012;119:2675-8.
5. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005;23:5074-87.
6. Ringdén O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002;20:4655-64.
7. Schmitz N, Beksac M, Bacigalupo A, et al. Filgrastim-mobilized peripheral blood progenitor cells versus bone marrow transplantation for treating leukemia: 3-year results from the EBMT randomized trial. Haematologica 2005;90:643-8.
8. Gallardo D, de la Cámara R, Nieto JB, et al. Is mobilized peripheral blood comparable with bone marrow as a source of hematopoietic stem cells for allogeneic transplantation from HLA-identical sibling donors? A case-control study Haematologica 2009;94:1282-8.
9. Vigorito AC, Bouzas LF, Moreira MC, et al. A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials. Rev Bras Hematol Hemoter 2011;33:283-9.
10. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007;110:2744-8.
11. Carlens S, Ringdén O, Remberger M, et al. Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 1998;22:755-61.
12. Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003;9:215-33.
13. Flowers ME, Parker PM, Johnston LJ, et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002;100:415-9.